Born from the Irvine Lab at MIT, Elicio’s platform technologies are able to deliver agents directly to the antigen-presenting cells of the lymph nodes and potentially revolutionize the field of therapeutic vaccines. As demonstrated in Nature Materials, Science Translational Medicine, and Nature, getting the right molecules to the right place reduces adjuvant toxicity while enhancing immune responses against an array of antigens in both cancer and infectious disease. Elicio is collaborating with biotech and pharma companies to address these serious illnesses.
Field: Cancer immunotherapy
CEO: Robert Connelly